Quest Diagnostics Stock-Based Compensation Growth & History (DGX)
Quest Diagnostics's stock-based compensation was $88.0M for fiscal 2025.
View full Quest Diagnostics company overviewQuest Diagnostics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $88.0M | $0 | 0.00% |
| 2024 | 2024-12-31 | $88.0M | $11.0M | +14.29% |
| 2023 | 2023-12-31 | $77.0M | $0 | 0.00% |
| 2022 | 2022-12-31 | $77.0M | −$2.0M | −2.53% |
| 2021 | 2021-12-31 | $79.0M | −$18.0M | −18.56% |
| 2020 | 2020-12-31 | $97.0M | $41.0M | +73.21% |
| 2019 | 2019-12-31 | $56.0M | −$5.0M | −8.20% |
| 2018 | 2018-12-31 | $61.0M | −$18.0M | −22.78% |
| 2017 | 2017-12-31 | $79.0M | $10.0M | +14.49% |
| 2016 | 2016-12-31 | $69.0M | $17.0M | +32.69% |
| 2015 | 2015-12-31 | $52.0M | $1.0M | +1.96% |
| 2014 | 2014-12-31 | $51.0M | $23.0M | +82.14% |
| 2013 | 2013-12-31 | $28.0M | −$22.0M | −44.00% |
| 2012 | 2012-12-31 | $50.0M | −$22.0M | −30.56% |
| 2011 | 2011-12-31 | $72.0M | $18.1M | +33.51% |
| 2010 | 2010-12-31 | $53.9M | −$21.1M | −28.15% |
| 2009 | 2009-12-31 | $75.1M | $4.5M | +6.34% |
| 2008 | 2008-12-31 | $70.6M | $13.7M | +24.15% |
| 2007 | 2007-12-31 | $56.9M | — | — |
Quest Diagnostics quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $23.0M | $2.0M | +9.52% |
| Q1 2026 | 2026-03-31 | $20.0M | −$2.0M | −9.09% |
| Q4 2025 | 2025-12-31 | $25.0M | −$2.0M | −7.41% |
| Q3 2025 | 2025-09-30 | $20.0M | $1.0M | +5.26% |
| Q2 2025 | 2025-06-30 | $21.0M | $1.0M | +5.00% |
| Q1 2025 | 2025-03-31 | $22.0M | $0 | 0.00% |
| Q4 2024 | 2024-12-31 | $27.0M | $8.0M | +42.11% |
| Q3 2024 | 2024-09-30 | $19.0M | $1.0M | +5.56% |
| Q2 2024 | 2024-06-30 | $20.0M | $4.0M | +25.00% |
| Q1 2024 | 2024-03-31 | $22.0M | −$2.0M | −8.33% |
| Q4 2023 | 2023-12-31 | $19.0M | −$3.0M | −13.64% |
| Q3 2023 | 2023-09-30 | $18.0M | $0 | 0.00% |
| Q2 2023 | 2023-06-30 | $16.0M | −$3.0M | −15.79% |
| Q1 2023 | 2023-03-31 | $24.0M | $6.0M | +33.33% |
| Q4 2022 | 2022-12-31 | $22.0M | $3.0M | +15.79% |
| Q3 2022 | 2022-09-30 | $18.0M | −$3.0M | −14.29% |
| Q2 2022 | 2022-06-30 | $19.0M | −$2.0M | −9.52% |
| Q1 2022 | 2022-03-31 | $18.0M | $0 | 0.00% |
| Q4 2021 | 2021-12-31 | $19.0M | −$15.0M | −44.12% |
| Q3 2021 | 2021-09-30 | $21.0M | −$11.0M | −34.38% |
| Q2 2021 | 2021-06-30 | $21.0M | $4.0M | +23.53% |
| Q1 2021 | 2021-03-31 | $18.0M | $4.0M | +28.57% |
| Q4 2020 | 2020-12-31 | $34.0M | $22.0M | +183.33% |
| Q3 2020 | 2020-09-30 | $32.0M | $20.0M | +166.67% |
| Q2 2020 | 2020-06-30 | $17.0M | $2.0M | +13.33% |
| Q1 2020 | 2020-03-31 | $14.0M | −$3.0M | −17.65% |
| Q4 2019 | 2019-12-31 | $12.0M | $4.0M | +50.00% |
| Q3 2019 | 2019-09-30 | $12.0M | −$7.0M | −36.84% |
| Q2 2019 | 2019-06-30 | $15.0M | $0 | 0.00% |
| Q1 2019 | 2019-03-31 | $17.0M | −$2.0M | −10.53% |
| Q4 2018 | 2018-12-31 | $8.0M | −$17.0M | −68.00% |
| Q3 2018 | 2018-09-30 | $19.0M | $2.0M | +11.76% |
| Q2 2018 | 2018-06-30 | $15.0M | −$5.0M | −25.00% |
| Q1 2018 | 2018-03-31 | $19.0M | $2.0M | +11.76% |
| Q4 2017 | 2017-12-31 | $25.0M | $8.0M | +47.06% |
| Q3 2017 | 2017-09-30 | $17.0M | $1.0M | +6.25% |
| Q2 2017 | 2017-06-30 | $20.0M | $2.0M | +11.11% |
| Q1 2017 | 2017-03-31 | $17.0M | −$1.0M | −5.56% |
| Q4 2016 | 2016-12-31 | $17.0M | $4.0M | +30.77% |
| Q3 2016 | 2016-09-30 | $16.0M | $4.0M | +33.33% |
| Q2 2016 | 2016-06-30 | $18.0M | $3.0M | +20.00% |
| Q1 2016 | 2016-03-31 | $18.0M | $6.0M | +50.00% |
| Q4 2015 | 2015-12-31 | $13.0M | $0 | 0.00% |
| Q3 2015 | 2015-09-30 | $12.0M | −$1.0M | −7.69% |
| Q2 2015 | 2015-06-30 | $15.0M | $2.0M | +15.38% |
| Q1 2015 | 2015-03-31 | $12.0M | $0 | 0.00% |
| Q4 2014 | 2014-12-31 | $13.0M | $9.0M | +225.00% |
| Q3 2014 | 2014-09-30 | $13.0M | $6.0M | +85.71% |
| Q2 2014 | 2014-06-30 | $13.0M | $1.0M | +8.33% |
| Q1 2014 | 2014-03-31 | $12.0M | $7.0M | +140.00% |
| Q4 2013 | 2013-12-31 | $4.0M | −$2.9M | −42.14% |
| Q3 2013 | 2013-09-30 | $7.0M | −$1.9M | −21.43% |
| Q2 2013 | 2013-06-30 | $12.0M | −$2.1M | −14.95% |
| Q1 2013 | 2013-03-31 | $5.0M | −$15.1M | −75.08% |
| Q4 2012 | 2012-12-31 | $6.9M | −$14.3M | −67.41% |
| Q3 2012 | 2012-09-30 | $8.9M | −$6.7M | −42.88% |
| Q2 2012 | 2012-06-30 | $14.1M | −$2.1M | −13.15% |
| Q1 2012 | 2012-03-31 | $20.1M | $1.1M | +5.93% |
| Q4 2011 | 2011-12-31 | $21.2M | $12.3M | +138.73% |
| Q3 2011 | 2011-09-30 | $15.6M | −$870,000 | −5.28% |
| Q2 2011 | 2011-06-30 | $16.2M | −$1.2M | −6.88% |
| Q1 2011 | 2011-03-31 | $18.9M | $7.8M | +70.26% |
| Q4 2010 | 2010-12-31 | $8.9M | −$12.8M | −59.11% |
| Q3 2010 | 2010-09-30 | $16.5M | −$3.7M | −18.33% |
| Q2 2010 | 2010-06-30 | $17.4M | −$1.6M | −8.53% |
| Q1 2010 | 2010-03-31 | $11.1M | −$3.0M | −21.03% |
| Q4 2009 | 2009-12-31 | $21.7M | — | — |
| Q3 2009 | 2009-09-30 | $20.2M | $7.4M | +58.46% |
| Q2 2009 | 2009-06-30 | $19.1M | — | — |
| Q1 2009 | 2009-03-31 | $14.1M | — | — |
| Q3 2008 | 2008-09-30 | $12.7M | — | — |
Quest Diagnostics stock-based compensation trends
Over the last five fiscal years, Quest Diagnostics's stock-based compensation decreased from $97.0M to $88.0M, a change of −$9.0M. The latest reported quarter, Q2 2026, shows $23.0M.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Quest Diagnostics source filings ↗